Holding website 
Nexodyn® AOS Wound Care Solution, cleared for sale by the FDA, is now available in the USA, promoted and commercialized by the leading Italian pharmaceutical company Angelini, as a result of an exclusive partnership with APR.
Nexodyn® AOS Wound Care Solution has been presented officially to Healthcare professionals during the last edition of the conference SAWC (Symposium of Advanced Wound Care) held in Las Vegas.
“With this latest product launch, Angelini aims to strengthen its position in the Wound Care market in the United States and worldwide. We look to provide healthcare professionals and patients with a range of wound treatment options based on innovative technologies, like TEHCLO® by APR, that offer important benefits to users” – states Todd Maddock, Angelini US CEO.
Thanks to its formulation, according to the FDA clearance, Nexodyn® AOS Wound Care Solution helps cleanse and moisten the wound micro-environment by removing dirt, debris and foreign material by flushing across the wound. Nexodyn® AOS Wound Care Solution is intended for use, under the supervision of healthcare professionals, to treat acute and chronic dermal lesions (such as leg ulcers, post-surgical wounds or 1st and 2nd degree burns) and minor cuts, burns, skin irritations and superficial abrasions.
Nexodyn® AOS Wound Care Solution, characterized by an acidic pH between 2.5 and 3.0, has excellent cell viability preservation features, so as not to negatively interfere with the natural physiological healing process and epthelialization. Its antimicrobial preservative effectiveness has been demonstrated by in vitro testing against the most common bacteria, fungi and viruses.